Most of the recent studies investigating the roles of FOXP2 in cancer have focused on noncoding RNA-mediated dysregulation of FOXP2, suggesting that FOXP2 has either oncogenic or tumor-suppressive effects on cancer development in different tumor contexts (Cuiffo et al., 2014; Du et al., 2020; Kim et al., 2019; Xu et al., 2022; Zhao et al., 2021). The gene discussed is FOXP2; the disease is cancer.